Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002131 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma
A Phase 2 study, sponsored by Otsuka America Pharmaceutical.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00002131 is a Phase 2 study that has completed, run by Otsuka America Pharmaceutical. The registered enrollment target is 28 participants.
The verdict
NCT00002131, a Phase 2 study, has completed, sponsored by Otsuka America Pharmaceutical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
To examine the safety and efficacy of two doses of vesnarinone in patients with AIDS-related Kaposi's sarcoma.
Interventions
- DRUG Vesnarinone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002131
The ClinicalTrials.gov registry entry for NCT00002131 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka America Pharmaceutical, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vesnarinone is the first listed.
NCT00002131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002131 about?
NCT00002131 is a clinical study titled "A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma". To examine the safety and efficacy of two doses of vesnarinone in patients with AIDS-related Kaposi's sarcoma.
What is the current status of trial NCT00002131?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants.
What interventions are being tested in trial NCT00002131?
The interventions under investigation include: Vesnarinone (DRUG).
Who is sponsoring clinical trial NCT00002131?
This trial is sponsored by Otsuka America Pharmaceutical, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.